Tag
Individualized cabergoline dosing guided by nadir prolactin levels achieves durable remission and safe pregnancy outcomes in women with prolactinomas, including those resistant or intolerant to bromocriptine.
This study evaluates the impact of lumpectomy margin widths on local recurrence in postmenopausal women with hormone receptor-positive DCIS undergoing lumpectomy, radiation, and endocrine therapy, suggesting minimal recurrence differences b
A phase 2 trial demonstrates that combining letrozole, abemaciclib, and metformin achieves a 32% response rate and 60% clinical benefit rate in ER+ endometrioid endometrial cancer, with notable efficacy in CTNNB1-mutated tumors and an inter
Results from the UTOLA trial reveal that ESR1 mutations, a hallmark of AI resistance in breast cancer, are present in 22% of metastatic NSMP low-grade endometrial cancer patients before endocrine therapy, suggesting a need for molecular str
This real-world study demonstrates that elacestrant provides a durable benefit for patients with ER+/HER2- ESR1-mutated metastatic breast cancer, maintaining efficacy across various treatment lines and in patients with visceral metastases o
A secondary analysis of the RxPONDER trial finds chemoendocrine therapy causes more lasting cognitive impairment than endocrine therapy alone in both pre- and postmenopausal women.
Two large prospective‑retrospective analyses confirm BCI as a robust prognostic biomarker in premenopausal HR+ breast cancer; its HOXB13/IL17BR (H/I) component predicted benefit from adding ovarian function suppression versus tamoxifen alon
This review analyzes the pivotal phase 3 trial demonstrating elinzanetant’s efficacy and safety in reducing vasomotor symptoms among women undergoing endocrine therapy for HR-positive breast cancer or prevention.
This article reviews a patient-level meta-analysis on prolonging endocrine therapy for early breast cancer in postmenopausal women, focusing on the benefits of additional aromatase inhibitor treatment after five years of initial therapy.
